Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation

Preclinical studies have demonstrated that the chemotherapeutic action of oxaliplatin, a third generation platinum derivative, is improved when combined with cetuximab, a monoclonal antibody inhibitor of epidermal growth factor receptors. To explore the mechanism of this synergistic benefit, we used...

Descripción completa

Detalles Bibliográficos
Autores principales: Balin-Gauthier, D, Delord, J-P, Pillaire, M-J, Rochaix, P, Hoffman, J-S, Bugat, R, Cazaux, C, Canal, P, Allal, B C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359709/
https://www.ncbi.nlm.nih.gov/pubmed/18182978
http://dx.doi.org/10.1038/sj.bjc.6604134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2359709/
https://www.ncbi.nlm.nih.gov/pubmed/18182978
http://dx.doi.org/10.1038/sj.bjc.6604134

Ejemplares similares